Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGF Cancer Vaccine in Inoperable, Late Stage NSCLC
NCT01444118Phase 3Terminated
- Sponsor
- Bioven
- Start
- Nov 2011
- Primary completion
- Dec 2014
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing EGF Vaccine with Best Supportive Care (2 arms). Primary endpoint: Overall Survival at 3 years. Started Nov 2011; status: terminated.
02
Drugs
cimavax egf
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01444118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01444118.